This strategic partnership marks an important milestone for Imexpharm to excel in producing high-quality branded medicines at reasonable costs, helping to reduce the financial burden on patients and at the same time ensuring access to healthcare services for all.
General Director, People's Physician, Pharmacist Tran Thi Dao and Mr. Samsoo Lee, CEO of Genuone Sciences Inc.
Under this strategic cooperation agreement, in the first phase, Genuone and Imexpharm will focus on identifying optimal product portfolios for the Vietnamese market. Together, the two parties will provide a wide range of medicines to address medical conditions such as cardiovascular disease, diabetes and other common health problems.
As part of the cooperation agreement, Genuone and Imexpharm will cooperate in drug registration, production and distribution in Vietnam, followed by technology transfer, including the transfer of advanced technology from Genuone to Imexpharm.
Currently, Imexpharm is a company that owns 3 EU-GMP standard factory clusters with 11 EU-GMP standard production lines. This has made Imexpharm the pharmaceutical company that owns the largest EU-GMP factory cluster and the largest number of EU-GMP production lines in Vietnam.
Source
Comment (0)